Press Release Hub logo
  • Submit a Release
  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Research
Medical Devices
Genetics
Clinical Trials
Health Technology
Other Health
Biotechnology
Pharmaceutical
Health
Science
RenMab RenMice Japan Patent Office

More Like This

Business Wire logo

Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform

(Graphic: Business Wire)

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Business Wire logo

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Business Wire logo

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

Business Wire logo

Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies

Business Wire logo

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Business Wire logo

Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development

PR Newswire associated0

NeoMab Fully Human Antibody Discovery Platform: A New Flexible Mouse Purchase Model Leading a New Trend in Antibody Drug Development

Pages

  • Home
  • All
  • ESG
  • Health
  • Technology
  • Finance
  • Contributors

Press Release Hub

  • Our Services
  • Submit a Release

Websites

  • PA Media Group
  • PA Mediapoint
  • Distribution Packages

© PA Media Group. 2025

Terms of Use

Privacy Policy

Contact Us